How US FDA’s Pharma Quality Office Fared In Pandemic’s Second Year

OPQ Director Kopcha looks back at a year that travel restrictions made especially challenging for application reviews, site surveillance, IT support and sleep. And ahead to new challenges around supply chain transparency and resilience.